



AIFA's Scientific-Technical Committee releases opinion on booster dose administration of Spikevax vaccine against COVID-19

On 28 October 2021 AIFA's Scientific-Technical Committee (CTS) expressed its opinion on the administration of a booster dose of the Spikevax (Moderna) vaccine against COVID-19. Taking note of EMA's decision, the CTS establishes to make the booster dose of the Spikevax vaccine available in subjects aged 18 years or older, at least six months after the second dose. The Committee also reiterates that, as already established for the Pfizer booster dose, this opportunity should be offered as a priority to subjects already indicated for the Comirnaty (Pfizer) vaccine.

The booster dose of the Spikevax vaccine will also be included in the list referred to in Law 648/96 to allow its heterologous use.